MYCROFT COGNITIVE SCIENCES, INC.
Solving complex problems such as cancer or diabetes becomes more successful by connecting different minds together in order to achieve greater results. Finding those who are interested in similar goals is an essential part to research development. To improve this process, Mycroft as an instance of IBM’s Watson can be used as an assistive tool for its cognitive computing system in Biomedical Research based on the principles of Team Science. Mycroft Cognitive Sciences aims to optimize efficiency and discovery of scientific research, grant submission and collaboration. Increasing the success of the Grant application process for research institutions and minimizing the time spent on grant submissions. Mycroft was born out of OHSL, where we have spent the last five years studying the grant application process both from inside the NIH and from the perspective of those institutions applying for funding, in the US and abroad.
Support Mycroft Cognitive Sciences on Wefunder.
INDO US CANCER KNOWLEDGE ALLIANCE (IUCKA)
The National Cancer Grid (NCG) was formed in August 2012 with the mandate of linking cancer centers across India. Currently few activities have been undertaken as joint or collaborative initiatives for research in cancer. OHSL is now leading the effort to develop new projects and programs that will fit within the scope of the NCG mandate.
See IUCKA’s presentation on YouTube.
OHSL TELESYNERGY LAB
The U.S. National Institutes of Health (NIH)’s Center for Information Technology (CIT) funded the development of Telesynergy technology for the NIH to utilize for expanding access of healthcare to disparate regions around the world. It uses the assistance of audio, video, and screen sharing and manipulation to allow doctors and medical advisors to simulate working side-by-side on their cases. Telesynergy brings doctors and patients, wherever they are, and whatever distance stretches between them, to a virtual space where they can communicate as though they are in close physical proximity—whether in relation to a patient’s treatment, or to share research on a medical subject.
Under a cooperative research and development collaboration agreement (CRADA) with NIH/CIT, NIH’s National Cancer Institute, and OHSL will upgrade and integrate Telesynergy solutions around the world.
OHSL has forges numerous partnerships between researchers and research institutions around the world. The following are just a few examples:
- Repurposing Niclosamide for Colon Cancer
OHSL partnered with Duke University’s Cancer Center and Tata Memorial Center to reformulate and repurpose Niclosamide as a colon cancer therapeutic. Niclosamide is an off-patent drug previously used to cure tapeworm disease. OHSL is working to identify the research partner and pharmaceutical manufacturer to bring this drug to a new patient population. The consortium has completed pre-clinical studies, and is now proceeding to the clinical trials phase. This is an ongoing project over two years with approximately USD $7 Million of grant funding from NIH.
- Radiation Sensitizers
This project took certain off-patent drugs that, when administered with radiation, improves the efficacy of the radiation and the efficacy of treatment. This international consortium was led by OHSL, and included:
- India Institute of Technology in New Delhi, India
- The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), supported by the Indian Department of Atomic Energy, located in Mumbai, India
- India’s Institute of Nuclear Medicine & Allied Sciences (INMAS) within India’s (DRDO) Defense Research and Development Organization in New Delhi, India
- Adyar Cancer Institute in Chennai, India
OHSL created, launched, and is currently coordinating this effort. Project is valued at $2M over 1 year, and will likely be extended.
- Connectivity and Capacity Building for Cancer Research
OHSL created and launched a successful international consortium to build clinical trial units in Pakistan, and build a new National Cancer Grid in India to connect 54 cancer centers throughout the country to one another, and also to promote capacity building and research in cancer.
Duke University provided training for the development and operation of the clinical trial units at Aga Khan University Hospital in Karachi. This was a 2-year project and cofounded by the existing partners and NIH, and valued at USD $11.5 Million.